Lung Carcinoma

Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining ≥1%), had … (full text at CIViC)

PMID 26918451 · Passiglia et al., 2016 · Open in CIViC

In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to bet… (full text at CIViC)

PMID 28472902 · Aguiar et al., 2017 · Open in CIViC

PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.

PMID 25891174 · Garon et al., 2015 · Open in CIViC

This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation o… (full text at CIViC)

PMID 27718847 · Reck et al., 2016 · Open in CIViC

In an in vivo study, mice injected with v242 show significantly reduced survival compared to mice expressing WT (p < 0.001) when treated with anti-PD-L1 antibody. Moreover mixing only 1% MC38 cells wi… (full text at CIViC)

PMID 30872362 · Gong et al., 2019 · Open in CIViC

Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement. CD72-ROS1 was identified in sequencing aft… (full text at CIViC)

PMID 26917690 · Subbiah et al., 2016 · Open in CIViC

TAPUR, a phase II basket trial, included a cohort of patients with advanced non-small lung cell carcinoma (NSCLC) harboring with CDKN2A loss or mutation and no RB mutations. Twenty-nine patients were … (full text at CIViC)

Open in CIViC

In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).

PMID 22619677 · Zhao et al., 2012 · Open in CIViC

In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival.

PMID 23111194 · Bradly et al., 2012 · Open in CIViC

In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence.

PMID 23111194 · Bradly et al., 2012 · Open in CIViC

A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC)

PMID 28490518 · Sen et al., 2017 · Open in CIViC

Ablation of the CBP paralog p300/EP300 has been identified as syntheticaly lethal in in CBP-knockout and CBP-deficient cancer cells and induced a G1-S cell-cycle arrest, followed by apoptosis. Genome-… (full text at CIViC)

PMID 26603525 · Ogiwara et al., 2016 · Open in CIViC

CRKL is an oncogene in a subset of NSCLC. Overexpression of CRKL induces cell transformation and resistance to epidermal growth factor receptor inhibitor treatment and suggest that therapeutic interve… (full text at CIViC)

PMID 22586683 · Cheung et al., 2011 · Open in CIViC

This work shows that across multiple cancer types, responses were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune c… (full text at CIViC)

PMID 25428504 · Herbst et al., 2014 · Open in CIViC

This study shows that across multiple cancer types, responses were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune… (full text at CIViC)

PMID 25428504 · Herbst et al., 2014 · Open in CIViC

CXCR4, a stromal-derived-factor-1 specific chemokine receptor, is highly expressed in non-small cell lung cancer (NSCLC) tissues and participates in cancer progression by regulating cell growth, apopt… (full text at CIViC)

PMID 27922681 · Xie et al., 2017 · Open in CIViC

In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

Ba/F3 cells expressing the G774V mutation were sensitive to the tyrosine kinase inhibitor dasatinib while wild-type expressing cells were not, as measured in a proliferation assay.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

The NCI-H2286 lung squamous cell carcinoma cell line, containing the DDR2 I638F mutation was shown to be sensitive (IC50 139nm) to dasatinib in-vitro. Dasatanib sensitivity was demonstrated in-vivo us… (full text at CIViC)

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

The HCC-366 lung adenosquamous carcinoma cell line, containing the DDR2 L239R mutation was shown to be sensitive (IC50 140nm) to dasatinib in-vitro. The authors were unable to establish tumors using t… (full text at CIViC)

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

In a phase II trial, patients with DLL3-expressing small cell lung carcinoma were treated with rovalpituzumab tesirine. Only patients with 1% or more tumor cells expressing DLL3 were enrolled. In this… (full text at CIViC)

PMID 31506387 · Morgensztern et al., 2019 · Open in CIViC

74 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma received at least one dose of rovalpituzumab tesirine in a phase 1 trial. 11 (18%) of 60 assessable patients … (full text at CIViC)

PMID 27932068 · Rudin et al., 2017 · Open in CIViC

A total of 106 Chinese NSCLC patients who had failed at least one chemotherapy regimen received gefitinib 250 mg once daily. Patients with EGFR mutations had a significantly higher overall response ra… (full text at CIViC)

PMID 19020901 · Xu et al., 2009 · Open in CIViC

In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including wether or not administrati… (full text at CIViC)

PMID 23749122 · Locatelli-Sanchez et al., 2013 · Open in CIViC

Out of a group of 19 EGFR exon 20 insertion NSCLC patients, 3 patients had EGFR M766_A767insASV mutation. One patient was 69 year old female neversmoker lung adenocarcinoma patient was given erlotini… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In this study, 4 patients with an EGFR exon 19 insertion and 6 patients with an EGFR exon 20 insertion (A763_Y764insFQEA) were enrolled. Hospital. Among patients with an exon 19 insertion, 3 received … (full text at CIViC)

PMID 28089594 · Lin et al., 2017 · Open in CIViC

In an in vitro study, MCF-7 cells expressing the EGFR A767_V769dup mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 10 nM. In comparison, cells e… (full text at CIViC)

PMID 21132006 · Harada et al., 2011 · Open in CIViC

In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutations and treated with erlotinib monotherapy, patients with EGFR A767_V769dupASV mutation (n=3) experienced prog… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR A859T mutation, EGFR A859T was reported to be sensitive to erlotinib treatment. The patient was initially treated with standard chemotherapy and subsequ… (full text at CIViC)

PMID 21317745 · Le Maignan et al., 2011 · Open in CIViC

In an in vitro study, a MCF-7 cell line expressing EGFR A859T demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGF… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

NSCLC with EGFR activating alterations are frequently treated with the tyrosine kinase inhibitor, osimertinib. Though initially very effective, cancers cells often develop resistance to osimertinib th… (full text at CIViC)

PMID 37481710 · Lu et al., 2023 · Open in CIViC

A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy n… (full text at CIViC)

PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC

Study was a Phase 3 clinical trial of erlotinib in non-small cell lung cancer patients who has progressed after standard chemotherapy. Study found significantly increased survival time for patients… (full text at CIViC)

PMID 16014883 · Tsao et al., 2005 · Open in CIViC

Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.

PMID 23344087 · Kim et al., 2013 · Open in CIViC